[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565950":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":64,"collaborators":21,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":21,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":21,"enrollmentInfo":75,"targetDuration":21,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":93,"whyStopped":21,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Microvisk Technologies Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Warfarin patients","EXPERIMENTAL","Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy",[13,14],"Procedure: Venepuncture","Other: Collection of relevant information",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Venepuncture","Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"OTHER","Collection of relevant information","Collect relevant information to ensure potential participant meets all inclusion\u002Fexclusion criteria.",[9],[28],{"name":29,"affiliation":30,"role":31},"Susan Shapiro","Oxford Haemophilia and Thrombosis Centre Oxford University Hospital NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Matthew Cust","CONTACT","+44 01844338276","matt.cust@microvisk.com",{"name":39,"role":35,"phone":36,"phoneExt":21,"email":40},"Microvisk Operations","operations@microvisk.com",[42],{"facility":43,"status":21,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Oxford Haemophilia and Thrombosis Centre","Oxford","Oxfordshire","OX3 7LD","United Kingdom","UK",{"type":50,"coordinates":51},"Point",[52,53],-1.25596,51.75222,{"lat":53,"lon":52},[56,59,63],{"name":29,"role":35,"phone":57,"phoneExt":21,"email":58},"01865225316","susie.shapiro@ouh.nhs.uk",{"name":60,"role":35,"phone":61,"phoneExt":21,"email":62},"Chris Deane","01865 225343","Christopher.Deane@ouh.nhs.uk",{"name":29,"role":35,"phone":21,"phoneExt":21,"email":21},{"type":65,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100565950","microvisk-continuous-blood-donation-study-100565950",false,"NCT06648837","Microvisk Continuous Blood Donation Study","Continuous Blood Donation for the Development of the Microvisk PT\u002FINR","Inclusion Criteria:\n\n* Currently undergoing Warfarin therapy.\n* Over 18 years old\n\nExclusion Criteria:\n\nA participant is not eligible for participation if ANY of the following criteria are met:\n\n* Participant is \\\u003C18 years of age\n* Participant is unable to give consent\n* Participant has been treated with Unfractionated Heparin, or Low Molecular Weight Heparin, within the last 7 days\n* Participant has, or is suspected of having, Anti-Phospholipid Syndrome (APS)\n* Participant is pregnant, or has been in the past 12 months\n* Participant is known to have HIV\u002FAIDS, is a carrier of Hepatitis A, B or C, has had tuberculosis or a tropical disease\n* Participant is suspected of intravenous drug use","ALL","18 Years",{"count":76,"type":77},2500,"ESTIMATED","INTERVENTIONAL",[80],"NA","Microvisk Technologies Ltd designs and develops test systems for monitoring the effectiveness of Warfarin and Warfarin-like medications.\n\nWarfarin and Warfarin-like medications are used to reduce the risk of stroke in people with an irregular heart rhythm (Atrial Fibrillation) or with mechanical heart valve replacements, as well as reducing the risk of recurrent Venous Thromboembolism.\n\nWarfarin dosing needs to be individualized. In order to correctly dose an individual in order to optimize the effectiveness of warfarin, and minimize the risk of bleeding, close monitoring of the degree of anticoagulation is required through regular blood testing. This test is known as PT\u002FINR (Prothrombin Time\u002FInternational Normalised Ratio). Simply, it is the measure of the amount of time (in seconds) it takes for your blood to clot.\n\nMicrovisk Technologies Ltd are developing new anticoagulant test strips for patients on warfarin or warfarin like medications. The blood collected as part of this study will be tested upon Microvisk's second generation Prothrombin\u002FInternational Normalized Ratio (PT\u002FINR) Test System. The donated blood will be used on ongoing development, validation, verification, and calibration projects. This study is being performed in partnership with the Oxford University Hospital (OUH) and Local Clinical Research Networks (LCRN) Thames Valley Core team, part of National Institute for Health and Care Research (NIHR).",[83,84,85],"Pulmonary Embolism (Diagnosis)","Deep Vein Thrombosis","Atrial Fibrillation (AF)",[87,88,89,90,91,92],"PT","INR","PT\u002FINR","Warfarin","Vitamin K agonist","POC testing","NOT_YET_RECRUITING","2024-11-20",{"date":96,"type":97},"2024-11-21","ACTUAL",{"date":99,"type":77},"2025-01-13",{"date":101,"type":77},"2029-11-01",{"name":5,"class":6},1]